Combined treatment against MCL1 and BCLXL killed the heterogeneous, resistant melanoma initiating cells (MICs) populations, and inhibited their self-renewability across multiple melanoma cell lines and patient samples. The gene discussed is BCL2L1; the disease is melanoma.